F5-peptide enhances the efficacy of the non-hormonal male contraceptive adjudin The bioavailability of the non-hormonal male contraceptive adjudin is low in rats due to the blood-testis barrier (BTB). This study was designed to examine if F5-peptide, an endogenously produced reversible BTB modifier, could enhance the bioavailability of adjudin to affect spermatogenesis and provide a contraceptive effect in rats while reducing systemic toxicity.
Looking back while moving forward: A justice-based, intersectional approach to research on contraception and disability For the first time in the twenty-first century, we have an emerging body of research regarding contraceptive use among adult women with disabilities in the United States.We highlight key findings from population-based analyses that found higher odds of female sterilization and lower odds of long-acting reversible contraception (LARC) use among women with disabilities compared to their peers without disabilities. We consider potential reasons underlying these differences, including discriminatory attitudes and policies that restrict the sexual and reproductive autonomy of people with disabilities.
Pharmacokinetic, biologic and epidemiologic differences in MPA- and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in women Access to safe and effective contraceptive choices is a reproductive right and contributes tremendously to improvements in maternal and child health. Progestin-only injectables, particularly intramuscularly injected depot medroxyprogesterone acetate (DMPA-IM), have received increased attention given findings suggesting a potential association with increased HIV risk. For women at high risk of HIV, the World Health Organization's Medical eligibility criteria for contraceptive use currently aggregate recommendations for all progestin-only injectables, including DMPA-IM, subcutaneously injected DMPA (DMPA-SC) and intramuscularly injected norethindrone/ norethisterone enanthate (NET-EN), except in the case of some drug interactions.
Hormonal contraception, breastfeeding and bedside advocacy: the case for patient-centered care Postpartum contraceptive decision making is complex, and recommendations may be influenced by breastfeeding intentions. While biologically plausible, concerns about the adverse impact of hormonal contraception on breast milk production have not been supported by the clinical evidence to date. However, the data have limitations, which can lead providers with different priorities around contraception and breastfeeding to interpret the data in a way that advances their personal priorities. Discrepancies in interpretations can lead to divergent recommendations for individual women and may cause conflict.
Response to the letter to the editor We appreciate Dr. Nelson's thoughtful comments on our article assessing the PATH questions (Parenting/Pregnancy Attitudes, Timing and How important is pregnancy prevention) and contraceptive method selection. We acknowledge that many clinicians and researchers want well-defined risks and benefits to guide precise treatments. However, the everyday reality of patient care is more nuanced, especially concerning the multidimensional issues of reproduction, contraceptive method choice and use.
Response to “study of contraceptive mobile app fails to provide convincing findings” Before we respond to the comments from the letter by Freundl et al., we would like to clarify a few points. It is in large parts a repetition from a previous letter published by that group, relating to our first contraceptive effectiveness study in the European Journal of Contraception, to which we responded . Since the authors do not refer to our response  in this letter, our response here will by necessity be repetitive. All of their comments can be addressed and stem primarily from misunderstandings of our manuscript.
A PATH to action perhaps? The article by Geist et al. creatively continues to advance our collective understanding of both pregnancy intendedness and cessation of contraception utilizing PATH questions (Pregnancy, Attitudes, Timing and How important is pregnancy prevention) . From more abstract perspective, however, this work seems to replace one close ended question “Would you like to become pregnant in the next year?” with four other closed-ended questions. One wonders, why do we not just ask one open ended question: “How do you think you would feel if you got pregnant in the coming year?” A happy response should prompt clinicians to direct their counseling toward preconception care.
Aviso para pacientes:
Esta página contiene información urológica dirigida a profesionales de la sanidad.
Si tiene algún problema relacionado con esta patología,
consulte con su urólogo o médico de familia.
Si desea información diseñada para pacientes y público general. puede visitar:
Portal de Información Urológica para Pacientes